BIOCRYST PHARMACEUTICALS INC Net Cash Provided by (Used in) Financing Activities in USD from 2010 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Biocryst Pharmaceuticals Inc quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2010 to Q1 2025.
  • Biocryst Pharmaceuticals Inc Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2025 was $529K.
  • Biocryst Pharmaceuticals Inc annual Net Cash Provided by (Used in) Financing Activities for 2024 was -$5.76M, a 118% decline from 2023.
  • Biocryst Pharmaceuticals Inc annual Net Cash Provided by (Used in) Financing Activities for 2023 was $32.5M, a 63.1% decline from 2022.
  • Biocryst Pharmaceuticals Inc annual Net Cash Provided by (Used in) Financing Activities for 2022 was $88M, a 75.5% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)

BIOCRYST PHARMACEUTICALS INC Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $529K +$1.58M Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-06
Q1 2024 -$1.05M -$6.13M -121% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-06
Q1 2023 $5.08M -$2.28M -31% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q1 2022 $7.36M +$4.46M +154% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q1 2021 $2.9M +$2.63M +990% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q1 2020 $266K -$19.8M -98.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q1 2019 $20M +$21.5M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q1 2018 -$1.48M -$50.2M -103% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q1 2017 $48.7M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q1 2014 $2.4M -$638K -21% Jan 1, 2014 Mar 31, 2014 10-Q 2014-05-09
Q1 2013 $3.04M -$8.89M -74.5% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-09
Q1 2012 $11.9M -$12.4M -50.9% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-09
Q1 2011 $24.3M Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-08

BIOCRYST PHARMACEUTICALS INC Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$5.76M -$38.2M -118% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-25
2023 $32.5M -$55.5M -63.1% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-25
2022 $88M -$272M -75.5% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-25
2021 $360M +$59.1M +19.7% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-27
2020 $301M +$201M +203% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-27
2019 $99.1M +$36.6M +58.5% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 $62.5M -$73.2M -53.9% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-01
2017 $136M +$112M +482% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-13
2016 $23.3M +$17.8M +325% Jan 1, 2016 Dec 31, 2016 10-K 2019-03-14
2015 $5.48M Jan 1, 2015 Dec 31, 2015 10-K 2018-03-12
2013 $30.3M +$13.3M +78.5% Jan 1, 2013 Dec 31, 2013 10-K 2014-03-10
2012 $17M -$6.8M -28.6% Jan 1, 2012 Dec 31, 2012 10-K 2014-03-10
2011 $23.8M +$22.9M +2759% Jan 1, 2011 Dec 31, 2011 10-K 2014-03-10
2010 $831K Jan 1, 2010 Dec 31, 2010 10-K 2013-03-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.